Immune response variables and viral mutations impact on COVID-19 reinfection and relapse

Abstract

The possibility of human reinfection with SARS-CoV-2, the coronavirus responsible for COVID-19, has not previously been thoroughly investigated. Although it is generally believed that virus-specific antibodies protect against COVID-19 pathogenesis, their duration of function and temporal activity remain unknown. Contrary to media reports that people retain protective antibody responses for a few months, science does not exclude reinfection and disease relapse shortly after initiating all immune responses during the primary onset of COVID-19. Despite production of antiviral antibodies, activated CD4+/CD8+ lymphocytes, and long-lived memory B cells, susceptibility to reinfection in humans for extended periods cannot be precluded due to repeated exposures to coronavirus or potential reactivation of the virus due to incomplete virus clearance. However, the mechanism of reinfection remains unknown. The biological characteristics of SARS-CoV-2, such as emergence of multiple mutations in the virus RNA molecules, transmissibility, rates of infection, reactivation and reinfection, can all affect the trajectory of the virus spread. Innate and adaptive immune response variables, differences in underlying diseases, and comorbidities, particularly in high risk individuals, can influence the dynamics of the virus infection. In this article, immune parameters and viral mutations pertaining to reinfection and disease relapse are reviewed and scientific gaps are discussed.

The Moderating Effect of Resilience on Mental Health Deterioration among COVID-19 Survivors in a Mexican Sample

“…The ANOVA results underscored the importance of relapses that emerged, with a small effect size. At first, SARS-CoV-2 was expected to induce a monophasic disease; however, the increasingly common cases of clinical recurrence of COVID-19 symptoms [ 60 , 61 , 62 ] have led to an investigation into whether all suspected COVID-19 relapses are due to a prolonged positive status or reinfection with a new strain [ 63 , 64 , 65 ]. Studies have indicated that clinical relapse could be due to a low level of neutralizing antibodies [ 66 ], whereas others have hypothesized that disease recurrence is due to an inflammatory syndrome because of an inappropriate immune response [ 61 ].…”

Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection

“…The risk factors for reinfection and, more importantly, its outcome (i.e., the prognosis factors for the severity of recurrent disease) are still poorly understood [ 4 , 6 , 7 ]. It is reasonable to assume that the main risk factor for repeated infection is an insufficiently protective immunity.…”

Clinical manifestations, treatment options, and comorbidities in COVID‐19 relapse patients: A systematic review

“…The new variants of the SARS‐CoV‐2 can bind to human cells, and the produced antibodies in the first infection could not efficiently opsonize them. Actually, these variants can lead to evading the immune response 15 …”